Pidi Tablet 1mg (Methylprednisolone)

Adult dosage

The initial dose may vary from 4mg to 48mg of methylprednisolone per day, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, although a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If satisfactory clinical results are not obtained after a reasonable period, discontinue treatment and switch to another appropriate therapy. The dose should be determined individually according to the disease being treated and the patient's response. After an adequate response is achieved, determine the appropriate maintenance dose by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Continuous monitoring of the dose is required. Situations that may require dose adjustment include remission or worsening of the disease, individual patient response to the drug, and the effects on the patient of exposure to stressful circumstances that are not directly related to the symptoms of the disease being treated. In the latter situation, it may be necessary to increase the dose for a period sufficient to satisfy the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the drug. For treatment of acute exacerbations of multiple sclerosis, administration of prednisolone 200mg daily for 1 week followed by prednisolone 80mg every other day for 1 month is effective (4mg of methylprednisolone is equivalent to 5mg of prednisolone). Alternate-day therapy is a regimen in which twice the daily dose is administered on one morning out of every two days. Although a single morning dose causes considerably less adrenal suppression than taking prednisolone (10mg) in 4 divided doses every 6 hours, there is evidence that when pharmacologic doses are used, some suppression of adrenal activity continues into the following day. Other corticosteroids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered short-acting (a single dose causes adrenocortical suppression for 1¼ to 1½ days); therefore, alternate-day therapy is recommended. In more severe diseases, a regimen of high doses divided throughout the day will usually be required for initial control of disease progression. The initial suppressive dose should be continued until a satisfactory clinical response is achieved, usually for 4 to 10 days in many allergic and collagen diseases. It is important to keep the initial period of suppressive dosing as short as possible, particularly if continuous use of alternate-day therapy is intended. Switch to ADT and gradually reduce the amount of corticosteroid given on alternate days. As disease progression comes under control, reduce the daily corticosteroid dose to the minimum effective dose as soon as possible, then change to an alternate-day schedule. If difficulties arise, it is preferable to administer 3 or even 4 times the daily dose on alternate days rather than merely doubling the daily dose. Once the patient is again controlled, attempt to reduce this dose to the minimum. The adrenal cortex is most active from 2 a.m. to 8 a.m. and least active from 4 p.m. to midnight. When administered during the period of peak activity (in the morning), exogenous corticosteroids suppress adrenal cortical activity the least. If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive corticosteroid dose divided throughout the day for control. Once control is achieved, the established alternate-day regimen may be tried again.

This drug should not be administered to certain patients. For instance, it should not be used in those with allergies to this drug or its components, nor in patients with infections without antibacterial coverage and systemic fungal infections. Moreover, it may be dangerous for patients with herpes simplex, herpes zoster, chickenpox, or those receiving live vaccines. This medication contains lactose and should not be given to patients with lactose intolerance or related genetic disorders. Caution is advised for certain patients. For example, patients with glaucoma, tuberculosis, keratitis, cataracts, electrolyte abnormalities, hypertension, thrombosis, or those who have recently undergone bowel surgery may have exacerbated symptoms due to the side effects of this medication. Patients with diabetes, osteoporosis, renal failure, hypothyroidism, fatty liver, myasthenia gravis, elderly patients, and epileptic patients require special observation and adjustment when using this drug. During treatment with this drug, various side effects may occur, including edema, increased blood pressure, muscle weakness, gastrointestinal symptoms, skin changes, neurological and endocrine abnormalities, necessitating careful monitoring of symptoms. Long-term use may result in adrenal insufficiency, thus sudden cessation is risky; gradual dose reduction is recommended. Additionally, susceptibility to infections may increase, so special care is needed to prevent infections such as chickenpox or measles. This drug interacts with many other medications. When taken with certain drugs, side effects may increase or efficacy may decrease, so consultation with a doctor or pharmacist is essential. Pregnant or breastfeeding women should use this medication only if absolutely necessary, as it may affect the fetus or newborn, and it is advisable to discontinue breastfeeding. In pediatric cases, growth retardation may occur, hence the minimum dosage should be used and growth status should be closely monitored. Elderly patients have a higher risk of side effects, so administration should be more cautious, and regular check-ups and monitoring are required during treatment. Caution is also advised regarding vaccination during treatment, and it is important to inform healthcare professionals about the use of this medication, as it can affect skin tests or the diagnosis of specific diseases.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral heads, steroid myopathy, loss of muscle mass, pathological fractures of the pelvis, osteoporosis, vertebral compression fractures, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, thirst, vomiting, stomach pain, loss of appetite, increased appetite, peptic ulcer, abdominal bloating, pancreatitis, esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, purpura, skin reaction suppression, purpura, acne, hirsutism, hair loss, hyperpigmentation, papilledema, increased intracranial pressure, seizures, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth suppression, latent diabetes symptoms, secondary adrenal insufficiency, pituitary apoplexy, impaired glucose tolerance, increased insulin or oral hypoglycemic agent requirements, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, subcapsular cataract, secondary ocular infections, retinal disorders, exophthalmos, negative nitrogen balance, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reaction, hypersensitivity reaction

This medicine may be sensitive to air or moisture, so it should be stored in a tightly closed container. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance

White round tablets

Package unit

30 tablets/bottle, 300 tablets/bottle